Medical Condition News

RSS

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

1 Jul 2014

Study uncovers new information on genes that may increase risk of cardiac arrhythmias

Two international research studies, both led by investigators affiliated with Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard, have uncovered new information about genes that may increase the risk of serious cardiac arrhythmias.

1 Jul 2014

A*STAR scientists pioneered a molecular connection between obesity and diabetes

Scientists from the Institute of Molecular and Cell Biology, a research institute under the Agency for Science, Technology and Research, have discovered that obese individuals lack a protein that is essential for regulating blood glucose levels, causing them to face higher risks of developing diabetes.

1 Jul 2014

Research finding may accelerate development of treatments for PTSD

Scientists at Yerkes National Primate Research Center, Emory University have identified a drug that appears to make memories of fearsome events less durable in mice.

1 Jul 2014

Adults in their 30s and 40s can slash heart disease risk, study finds

The heart is more forgiving than you may think -- especially to adults who try to take charge of their health, a new Northwestern Medicine- study has found.

1 Jul 2014

Vitamin D boost may prevent early death from heart disease and cancer

A vitamin D boost may prevent early death from heart disease and cancer, according to a large scale study by Mount Sinai and a consortium of international collaborators, published online in the June issue of BMJ.

1 Jul 2014

New Tel Aviv University study finds link between Alzheimer's and brain hyperactivity

Patients with Alzheimer's disease run a high risk of seizures. While the amyloid-beta protein involved in the development and progression of Alzheimer's seems the most likely cause for this neuronal hyperactivity, how and why this elevated activity takes place hasn't yet been explained - until now.

1 Jul 2014

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma.

1 Jul 2014

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT) has approved LemtradaTM (alemtuzumab) for adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features.

30 Jun 2014

Omega-3 PUFAs offer an affordable way to reduce effects of traumatic brain, spinal cord injuries

The omega-3 polyunsaturated fatty acids (PUFAs) found in seafood and marine oils called EPA and DHA may offer a simple, affordable way to reduce the effects of traumatic brain and spinal cord injuries by decreasing inflammation and nerve cell damage.

30 Jun 2014

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.

30 Jun 2014

Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

Lombard Medical, Inc, a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), exhibited its Aorfix Endovascular stent graft system at the 18th international experts' symposium, Critical Issues in Aortic Endografting, in Malmö, Sweden on June 27-28, 2014.

30 Jun 2014

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

By switching off a single gene, scientists at Columbia University's Naomi Berrie Diabetes Center have converted human gastrointestinal cells into insulin-producing cells, demonstrating in principle that a drug could retrain cells inside a person's GI tract to produce insulin.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Genervon Biopharmaceuticals LLC ("Genervon") today announced that it has analyzed and generated a Biomarker Data Report for its recent Phase 2a clinical trial for ALS disease modification.

30 Jun 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

ALS stands for Amyotrophic Lateral Sclerosis, better known as “Lou Gehrig’s Disease”. It is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord.

30 Jun 2014

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Engineers and neuroscientists at Duke University have developed a method to measure the response of an individual neuron to transcranial magnetic stimulation (TMS) of the brain. The advance will help researchers understand the underlying physiological effects of TMS -- a procedure used to treat psychiatric disorders -- and optimize its use as a therapeutic treatment.

30 Jun 2014

Modified classification system finds over one-third of knee replacements as inappropriate

New research reports that more than one third of total knee replacements in the U.S. were classified as "inappropriate" using a patient classification system developed and validated in Spain. The study, published in Arthritis & Rheumatology, a journal of the American College of Rheumatology (ACR), highlights the need for consensus on patient selection criteria among U.S. medical professionals treating those with the potential need of knee replacement surgery.

30 Jun 2014

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled.

30 Jun 2014

Medical Condition News

Researchers develop new way to identify potential therapeutic targets for drug resistant melanoma

Study uncovers new information on genes that may increase risk of cardiac arrhythmias

A*STAR scientists pioneered a molecular connection between obesity and diabetes

Research finding may accelerate development of treatments for PTSD

Adults in their 30s and 40s can slash heart disease risk, study finds

Vitamin D boost may prevent early death from heart disease and cancer

New Tel Aviv University study finds link between Alzheimer's and brain hyperactivity

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Omega-3 PUFAs offer an affordable way to reduce effects of traumatic brain, spinal cord injuries

Actavis seeks FDA ANDA approval for generic Zubsolv, confirms patent challenge

Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

Switching off a single gene converts human gastrointestinal cells into insulin-producing cells

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Genervon generates biomarker data for its Phase 2a clinical trial for ALS

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Amyotrophic lateral sclerosis in veterans: an interview with Milan Michael Karol, The Robert Packard Center for ALS Research at Johns Hopkins

Novel method to measure neuron response to transcranial magnetic stimulation of the brain

Modified classification system finds over one-third of knee replacements as inappropriate

Light-sensitive molecule enables noninvasive silencing of neurons

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News